Literature DB >> 4108871

Immunologic enhancement of allogeneic tumor growth with soluble histocompatibility-2 antigens.

L W Law, E Appella, P W Wright, S Strober.   

Abstract

Soluble, partially purified, histocompatibility antigens that were obtained from the membranes of A/J spleen cells have been assayed for their capacity to elicit immunologic enhancement of two tumors of A-strain origin: YAA-C1 and Sarcoma I. Crude membrane material and a partially purified, soluble antigen that were contained in a specific fraction, obtained after chromatography on a Sephadex G-150 column, elicited enhancement; this fraction has been shown to contain immunogenic histocompatibility-2(a) antigens as well as alloantigenic specificities that were detected serologically. Another soluble fraction did not induce enhancement; this fraction has been shown to contain antigens other than H-2. Passive enhancement of both tumors was achieved with antisera produced in allogeneic mice that were inoculated with crude membrane material or with a fraction obtained by Sephadex G-150 chromatography. These antisera contained cytotoxic and/or hemagglutinating antibodies. Immunologic enhancement was specific. A readily enhanceable tumor, Py 89, of C57BL origin was not enhanced with anti-H-2(a) antisera. These results suggest strongly that all important H-2(a) transplantation antigenic determinants of spleen cells can be recovered by partial papain digestion and fractionation on a Sephadex G-150 column.

Entities:  

Mesh:

Substances:

Year:  1971        PMID: 4108871      PMCID: PMC389594          DOI: 10.1073/pnas.68.12.3078

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  14 in total

1.  THE ROLE OF THYMUS IN TRANSPLANTATION RESISTANCE INDUCED BY POLYOMA VIRUS.

Authors:  R C TING; L W LAW
Journal:  J Natl Cancer Inst       Date:  1965-04       Impact factor: 13.506

2.  Studies on the mechanism of immunological enhancement of tumor homografts. I. Specificity of immunological enhancement.

Authors:  G MOLLER
Journal:  J Natl Cancer Inst       Date:  1963-06       Impact factor: 13.506

3.  Acceptance of tumor homografts by mice injected with antiserum. II. Effect of time of injection.

Authors:  N KALISS
Journal:  Proc Soc Exp Biol Med       Date:  1956-03

4.  Acceptance of tumor homografts by mice injected with antiserum. I. Activity of serum fractions.

Authors:  N KALISS; A A KANDUTSCH
Journal:  Proc Soc Exp Biol Med       Date:  1956-01

5.  Immunogenic properties of papain-solubilized alloantigen.

Authors:  R J Graff; S G Nathenson
Journal:  Transplant Proc       Date:  1971-03       Impact factor: 1.066

6.  Demonstration of H-2 isoantigens and polyoma specific tumor antigens by measuring colony formation in vitro.

Authors:  I Hellström; H O Sjögren
Journal:  Exp Cell Res       Date:  1965-10       Impact factor: 3.905

Review 7.  Immunological enhancement.

Authors:  N Kaliss
Journal:  Int Rev Exp Pathol       Date:  1969

8.  Immunogenic properties of papain-solubilized H-2 alloantigens.

Authors:  R J Graff; D L Mann; S G Nathenson
Journal:  Transplantation       Date:  1970-07       Impact factor: 4.939

Review 9.  Immunologic enhancement.

Authors:  G D Snell
Journal:  Surg Gynecol Obstet       Date:  1970-06

10.  Serological and immunogenic activity of soluble mouse transplantation antigens controlled by the H-2 locus.

Authors:  S Strober; E Appella; L W Law
Journal:  Proc Natl Acad Sci U S A       Date:  1970-10       Impact factor: 11.205

View more
  3 in total

1.  Induction of immunological tolerance to soluble histocompatibility-2 antigens of mice.

Authors:  L W Law; E Appella; S Strober; P W Wright; T Fischetti
Journal:  Proc Natl Acad Sci U S A       Date:  1972-07       Impact factor: 11.205

2.  Regeneration of the surface glycoproteins of a transplantable mouse tumor cell after treatment with neuraminidase.

Authors:  R C Hughes; B Sanford; R W Jeanloz
Journal:  Proc Natl Acad Sci U S A       Date:  1972-04       Impact factor: 11.205

3.  Glioblastoma multiforme: a controlled trial to assess the value of specific active immunotherapy in patients treated by radical surgery and radiotherapy.

Authors:  H J Bloom; M J Peckham; A E Richardson; P A Alexander; P M Payne
Journal:  Br J Cancer       Date:  1973-03       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.